Back to top
more

ADC Therapeutics (ADCT)

(Delayed Data from NYSE)

$2.64 USD

2.64
420,496

0.00 (0.00%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $2.64 0.00 (0.00%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ADC Therapeutics SA (ADCT) and CytomX Therapeutics (CTMX) have performed compared to their sector so far this year.

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 4.92% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Puma Biotech (PBYI) Tops Q3 Earnings Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 13.33% and 3.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Ligand (LGND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%

by Zacks Equity Research

Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.

Zacks Equity Research

Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised

by Zacks Equity Research

Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.

Zacks Equity Research

Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up

by Zacks Equity Research

Novo Nordisk (NVO) reports weaker-than-expected second-quarter 2023 results, missing both earnings and sales estimates. Management, however, raises 2023 guidance.

Zacks Equity Research

Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues

by Zacks Equity Research

Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.

Zacks Equity Research

Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales

by Zacks Equity Research

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.

Zacks Equity Research

Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.

Zacks Equity Research

Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance

by Zacks Equity Research

Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.

Zacks Equity Research

Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises

by Zacks Equity Research

Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.

Zacks Equity Research

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.

Zacks Equity Research

Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.

Zacks Equity Research

Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates

by Zacks Equity Research

Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -31.82% and 44.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MannKind (MNKD) Reports Break-Even Earnings for Q2

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 100% and 15.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.

Zacks Equity Research

Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line

by Zacks Equity Research

Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.

Zacks Equity Research

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

by Zacks Equity Research

Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. The company raises its financial outlook for full-year Caplyta sales.

Zacks Equity Research

Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.

Zacks Equity Research

Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View

by Zacks Equity Research

Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.

Zacks Equity Research

Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus

by Zacks Equity Research

Editas (EDIT) reports mixed second-quarter 2023 results. EDIT-301 studies remain on track to provide updates by the end of the year. The stock of the company rises about 6% on Wednesday.

Zacks Equity Research

Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.